Pro-angiogenic and osteogenic composite scaffolds of fibrin, alginate and calcium phosphate for bone tissue engineering

Nupur Kohli1,2, Vaibhav Sharma1, Alodia Orera3, Prasad Sawadkar1, Nazanin Owji4, Oliver G Frost1, Russell J Bailey5, Martyn Snow6, Jonathan C Knowles4,7,8,9, Gordon W Blunn10 and Elena García-Gareta1,4

Abstract
Due to the limitations of bone autografts, we aimed to develop new composite biomaterials with pro-angiogenic and osteogenic properties to be used as scaffolds in bone tissue engineering applications. We used a porous, cross-linked and slowly biodegradable fibrin/alginate scaffold originally developed in our laboratory for wound healing, throughout which deposits of calcium phosphate (CaP) were evenly incorporated using an established biomimetic method. Material characterisation revealed the porous nature and confirmed the deposition of CaP precursor phases throughout the scaffolds. MC3T3-E1 cells adhered to the scaffolds, proliferated, migrated and differentiated down the osteogenic pathway during the culture period. Chick chorioallantoic membrane (CAM) assay results showed that the scaffolds were pro-angiogenic and biocompatible. The work presented here gave useful insights into the potential of these pro-angiogenic and osteogenic scaffolds for bone tissue engineering and merits further research in a pre-clinical model prior to its clinical translation.

Keywords
Bone tissue engineering, angiogenic, osteogenic, fibrin, calcium phosphate

Date received: 19 February 2021; accepted: 9 March 2021

Introduction
The current treatment options for restoring bone defects involve the use of autologous bone grafts, allogeneic bone grafts and alloplastic materials. As it stands, autograft bone substitute is benchmarked as the gold standard treatment for offering osteoinductive and osteoconductive properties. However, this is associated with complications such as donor site morbidity, limited bone supply and increased risk of infection. As a result, many attempts have been made to fabricate bone implants that can offer suitable biological and mechanical properties. Similarly, the emergence of bone tissue engineering has led to the introduction of novel strategies that can serve as effective bone graft substitutes. Nevertheless, successful translation of such techniques, still remains a significant challenge.

The naturally occurring biodegradable polymer fibrin is the first bio-scaffold built by our body following tissue injury. Formation of a fibrin scaffold initiates haemostasis and provides a temporal matrix that supports cellular activity, including deposition of a new extracellular matrix

1Regenerative Biomaterials Group, The RAFT Institute & The Griffin Institute, Northwick Park & Saint Mark’s Hospital, London, UK
2Department of Mechanical Engineering, Imperial College London, London, UK
3Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain
4Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London, London, UK
5The NanoVision Centre, School of Engineering and Materials Science, Queen Mary University of London, London, UK
6Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, UK
7Department of Nanobioscience and NBM Global Research Centre for Regenerative Medicine, Dankook University, Cheonan, Republic of Korea
8The Discoveries Centre for Regenerative and Precision Medicine, UCL Campus, London, UK
9UCL Eastman-Korea Dental Medicine Innovation Centre, Dankook University, Cheonan, Republic of Korea
10School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK

Corresponding author:
Nupur Kohli, Department of Mechanical Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.
Email: n.kohli@imperial.ac.uk
(ECM). For tissue engineering applications, fibrin possesses excellent biocompatibility, pro-angiogenic and bioactive properties. However, its bio-degradable and mechanical properties are poor, thus limiting its use.\textsuperscript{2,3} Nevertheless, the pro-angiogenesis of the material makes it attractive for regeneration of highly vascularised tissues such as bone.\textsuperscript{4,5} In bone repair and regeneration, the main strategy is to combine fibrin with other polymers to create composites that in some cases include a ceramic component.\textsuperscript{4,5} Alginate is an anionic polysaccharide that conversely does not have the excellent biological properties of fibrin. Nevertheless, when in contact with divalent ions like Ca\textsuperscript{2+}, alginate is cross linkable, allowing the polysaccharide to maintain its form.\textsuperscript{10} When both fibrin and alginate are combined to form a composite scaffold the limitations of both biomaterials are overcome. By cross-linking the composite material, its biodegradation is slowed and the mechanical properties are enhanced. Our laboratory has developed a porous, cross-linked fibrin/alginate scaffold for the treatment of acute full thickness skin wounds and is currently in clinical trials.\textsuperscript{11–14} The scaffold has exhibited promising advantages in terms of retarding degradation and improving cell ingress, thus enhancing tissue regeneration and establishment of a blood supply.\textsuperscript{11,12} Since angiogenesis is key for successful bone regeneration,\textsuperscript{2,3} we hypothesized that our pro-angiogenic fibrin/alginate scaffold could be used for bone tissue engineering applications by adding an osteogenic component to the scaffold, such as a calcium-phosphate (CaP).

The biomineral present in bone is a CaP phase that has been defined as a poorly crystalline, highly substituted apatite consisting of very small crystals.\textsuperscript{15,16} Implants made of or incorporating CaP, or coated with it, show improved interaction with the surrounding bone tissue. Biomaterials incorporating CaP are often regarded as osteoconductive and sometimes they can be osteoinductive as well.\textsuperscript{1} However, a current limitation of CaP materials is their composition. The nanometer-sized platelet or needle crystals in bone incorporate several ionic substitutions, for example, Na\textsuperscript{+}, Sr\textsuperscript{2+} and Mg\textsuperscript{2+} in Ca\textsuperscript{2+} sites or CO\textsubscript{3}\textsuperscript{2−} in OH\textsuperscript{−} (A-substitution) and PO\textsubscript{4}\textsuperscript{3−} sites (B-substitution). Currently, CaP phases used for bone repair that is, hydroxyapatite [Ca\textsubscript{10}(PO\textsubscript{4})\textsubscript{6}(OH)\textsubscript{2} with Ca/P = 1.67] or β-tricalcium phosphate [β-Ca\textsubscript{3}(PO\textsubscript{4})\textsubscript{2} with Ca/P = 1.50] do not possess the chemical versatility of bone mineral. Consequently, efforts are being spent on producing CaP materials consisting of precursor phases that is, amorphous calcium phosphate [Ca\textsubscript{10}(PO\textsubscript{4})\textsubscript{2}·2H\textsubscript{2}O where z = 3–4.5 in basic conditions and M\textsubscript{2}(Ca\textsubscript{3}H\textsubscript{2}PO\textsubscript{4})\textsubscript{4·z}H\textsubscript{2}O) where z is unknown and M is typically a monovalent cation (Na\textsuperscript{+}, K\textsuperscript{+}, NH\textsubscript{4}\textsuperscript{+}) in acidic conditions; Ca/P = 0.67–1.50] or octacalcium phosphate [Ca\textsubscript{10}H\textsubscript{10}(PO\textsubscript{4})\textsubscript{6}·5H\textsubscript{2}O with Ca/P = 1.33]. These precursor CaP phases can be rapidly converted to apatite after implantation.\textsuperscript{15} However, production of these precursor phases in granular form has limited usability. Therefore, combination of them with a bioactive polymeric fibrous matrix would increase their clinical uses, shown by Chahal et al.\textsuperscript{17} and Kawai et al.\textsuperscript{18} Such precursor phases could be deposited on a bioactive matrix like our fibrin/alginate scaffold by biomimetic deposition following immersion in simulated body fluids.\textsuperscript{19,20}

The aim of this study was to develop new composite biomaterials with pro-angiogenic and osteoesthetic properties to be used as scaffolds in bone tissue engineering applications. For this purpose, a porous, cross-linked and slowly biodegradable fibrin/alginate scaffold originally developed in our laboratory for wound healing applications was used, throughout which deposits of CaP precursor phases were evenly incorporated using an established biomimetic method.

Materials and methods

Preparation of composite scaffolds

Composites were prepared by immersing the fibrin/alginate (FA) scaffolds in 5× concentrated simulated body fluid (SBF) solutions resulting in two prototypes.\textsuperscript{19,20} The FA scaffolds were previously manufactured in our laboratory using custom made methods.\textsuperscript{11–14} Briefly, reagents needed for manufacturing the FA matrix\textsuperscript{21} were whisked into a white foam that was casted on a mould where the foam was allowed to clot for 1 h at 37°C before chemical crosslinking with 0.2% vol/vol glutaraldehyde (Sigma-Aldrich, UK) in 80% ethanol/20% MES [2-(N-morpholino ethanesulfonic acid (69889, Sigma UK), 0.1 M, pH = 7.4] buffer for 4 h at room temperature. The scaffolds were then washed with 0.1% wt/vol sodium borohydride (452882, Sigma-Aldrich, UK) in diH\textsubscript{2}O and diH\textsubscript{2}O at room temperature, and finally lyophilised for 36 h at −40°C (Virtis Genesis Freeze Dryer, Biopharma, UK).

Fibrin/alginate-CaP1 (FACA\textsubscript{1}) was prepared by immersing fibrin/alginate scaffolds in SBF-1 solution comprising, 0.695 g of CaCl\textsubscript{2}; 0.760 g of MgCl\textsubscript{2}; 6H\textsubscript{2}O; 0.880 g of NaHCO\textsubscript{3} and 0.570 g of K\textsubscript{2}HPO\textsubscript{4}; 3H\textsubscript{2}O added to 0.4 L of distilled water (dH\textsubscript{2}O). Following this, the pH of the solution was adjusted to 6.0 using 1 M HCl, after which, 0.560 g of KCl and 20.135 g of NaCl were added to the solution. Finally, the pH of the solution was adjusted to 6.5 using 1 M NaOH. 1 × 1 cm pieces of FA scaffolds were immersed in SBF-1 solution for 24 h with constant stirring at 150 rpm on an orbital shaker at 37°C. After the immersion time, scaffolds were removed from the SBF-1 solution, washed with dH\textsubscript{2}O in an ultrasonic water cleaner for 60 s, frozen at −80°C and lyophilised.

To prepare the fibrin/alginate-CaP2 (FACA\textsubscript{2}) scaffolds, the dried FACA\textsubscript{1} scaffolds were immersed in SBF-2 solution, comprising 20.135 g of NaCl, 0.695 g of CaCl\textsubscript{2} and 0.570 g of K\textsubscript{2}HPO\textsubscript{4}; 3H\textsubscript{2}O added to 0.4 L of dH\textsubscript{2}O. The pH of this solution was adjusted to 6.0 with 1 M HCl. The
scaffolds were immersed in SBF-2 solution for 48 h with constant stirring at 60 rpm on an orbital shaker at 37°C. After the immersion time, scaffolds were washed, frozen and lyophilised.

All solutions were filtered with a 0.22 µm PES membrane before use. FA scaffolds immersed in dH2O were used as controls. All scaffolds were weighed pre and post-immersion to examine a change in the net weight as a result of the coating procedure.

Material characterisation of composite scaffolds

Scanning electron microscopy (SEM) and energy dispersive X-ray spectroscopy (EDX). Lyophilised scaffolds were carbon coated before observation under SEM and EDX analysis. SEM microphotographs were taken at 100× and 10,000×, and obtained at 10 kV using the Inspect F, FEI Company, The Netherlands. Morphology of CaP crystal deposits was studied from the SEM images. Elemental analysis of the scaffolds and Ca/P ratio were studied from the EDX spectra that were obtained at 10 kV using the X-Act, Oxford Instruments, UK.

Fourier transform infrared spectroscopy (FTIR) and x-ray diffraction (XRD). Analysis of functional groups in the CaP deposits was carried out by FTIR. Spectra were obtained by placing the scaffolds in contact with Attenuated Total Reflectance accessory (Golden Gate ATR, Specac, UK). Spectrum software v 5.0.1 (Perkin-Elmer, UK) identified the peak intensities of each chemical group (the wavenumber was fixed between 500 and 4000 cm⁻¹ with a resolution of 4 cm⁻¹).

Phase composition and crystallinity of the CaP deposits were studied by XRD using a RIGAKU D/max 2500 Diffractometer operated at 40 kV and 80 mA with graphite-filtered Cu Kα radiation. Data was collected from 2θ = 5° to 80° with a step size of 0.03°.

Rheology. To examine the viscoelastic properties of the scaffolds, we used a Kinexus Rheometer (Malvern Instruments, UK) in its oscillatory mode. Hydrated 2 × 2 cm pieces of samples were placed between two 20 mm diameter parallel plates. There was a 0.3 mm gap between the plates. One sample was measured at a time. An integrated temperature controller was used to maintain the temperature of the sample stage at 20°C. The ‘amplitude sweep’ and the ‘frequency sweep’ measurement was carried out on each sample. The ‘amplitude sweep’ was performed by applying controlled stresses that were linearly increased from 0.05% to 5%. Strains corresponding to the stresses were recorded. The oscillatory frequency was maintained at 1 Hz. The maximum strain within the linear viscoelastic region (LVER) was chosen from the ‘amplitude sweep’. The shear or storage modulus G’ was calculated for all the samples.

In vitro biodegradability. Scaffolds were cut into 5 × 5 mm square pieces prior to treatment with 0.5% trypsin at pH 7.2 at 37°C for up to 72 h. Scaffolds were immersed in PBS alone as controls. Demineralised bone matrix (DBM) 5 × 5 mm square pieces were also used as a control to examine how quickly or slowly FACaP scaffolds degrade in comparison to this clinically used material. Samples were imaged macroscopically using canon camera and microscopically using a stereomicroscope at 0, 18, 24, 42, 48 and 72 h.

In vitro cell work

In vitro response of inflammatory cells. As previously suggested by our group, we seeded macrophages on scaffolds to examine a difference in the pro-inflammatory nitric oxide (NO) production. RAW264.7 cell line was cultured as per the manufacturer’s guidelines (Sigma,
UK). At passage 2, $1 \times 10^5$ cells were directly seeded onto the scaffolds, previously cut into 5mm x 5mm pieces. The scaffolds were sterilised using 70% ethanol, followed by three washes in PBS, prior to cell seeding. Two h after cell seeding, 1 ml of DMEM media with or without 1 µg/ml of lipopolysaccharide (LPS) was added to the wells. After 24 h of incubation at 37°C, media was harvested for the analysis of NO production using Griess reagent system (Promega, UK). Briefly, 50 µl of media from the wells was added to a 96-well plate, followed by 50 µl sulphanilamide and 50 µl N-1-naphthylethylenediamine dihydrochloride (NED). Absorbance at 520 nm was measured by microplate reader and nitrite concentrations were calculated using a standard nitrite curve.

Cell seeding and culture of osteoprogenitor cells. MC3T3-E1 subclone mouse pre-osteoblasts (osteoprogenitor cells) were used in our study. Scaffolds were cut into 5 x 5 mm pieces and sterilised with 70% IMS, washed three times with PBS and placed in flat-bottomed-24 well ultra-low attachment plates. The scaffolds were seeded with $1 \times 10^5$ MC3T3-E1 cells in 20 µl media. After seeding, the plates were incubated for 3 h at 37°C with 5% CO$_2$ to allow cells to attach to the scaffolds. Then, 1 ml of αMEM (Minimum Essential Medium Eagle Alpha Modification with 1% antibiotics and 10% fetal calf serum) with (+OM) or without (−OM) osteogenic supplements (50 µg/ml ascorbic acid, 10 mM β-glycerophosphate and 100 nM dexamethasone) was added per well and cultured over a 28-day period at 37°C with 5% CO$_2$. Cell viability, proliferation, infiltration and osteogenic differentiation under both +OM and −OM conditions were assessed as described in the next sections.

Cell viability and proliferation of osteoprogenitor cells. Seeded scaffolds were assessed for cell incorporation and viability using Live/Dead cell staining according to the manufacturer’s guidelines (Sigma), wherein live cells fluoresce green and dead cells fluoresce red. Briefly, scaffolds were washed in PBS prior to staining with the live/dead staining solution and then the staining procedure was performed in the dark for 30 min at 37°C and 5% CO$_2$. Live and dead cells were visualized by fluorescence imaging and confocal microscopy.

Seeded scaffolds were transferred to fresh 24 well plates and 1 ml of alamarBlue® working solution (diluted 10X from stock solution with phenol free Dulbecco’s Modified Eagles Medium supplemented with 10% FCS and 1% antibiotics) was added per well. Samples were incubated at 37°C with 5% CO$_2$ for 3 h, after which each wells’ content was transferred to a cuvette and absorbance measured at 570 nm in a UV/vis spectrophotometer.

Infiltration and migration of osteoprogenitor cells. Seeded scaffolds were fixed in 10% formalin, processed and cut into 4 µm sections that were deparaffinized, rehydrated and washed in distilled water before applying Fluoroshield™ with DAPI mounting media (F6057, Sigma, Gillingham, UK) that was left to set for 5 min at room temperature. The sections were then covered and the edges sealed with nail varnish before imaging with a confocal scanning laser microscope (Leica DMIRE2, Leica, Wetzlar, Germany). Sections were tile-scanned for the entire XY plane of the scaffold and then merged using 5% overlap automated function of the confocal microscope.

Osteogenic differentiation of osteoprogenitor cells. Osteopontin is a non-collagenous bone ECM protein that is commonly used as an early marker of osteogenic differentiation and in this study was assessed by osteopontin immunostaining of paraffin-embedded sections. Briefly, antigen retrieval was performed by heat mediated antigen retrieval using sodium citrate buffer at pH 6. After antigen retrieval the sections were blocked using 5% bovine serum albumin at 35°C for 1 hour and stained with primary anti-osteopontin antibody (1:50, abcam ab8448) at 4°C overnight. Following this, the sections were stained using the Alexa fluor 546 secondary antibody for 2 h at room temperature. The sections were then washed and mounted with DAPI based mounting media, cover slipped and visualised using Leica DMIRE2 confocal microscope (Leica, Wetzlar, Germany). Furthermore, mineralisation was assessed with Von Kossa staining of paraffin-embedded sections as previously described.

Ex ovo chorioallantoic membrane (CAM) assay
Pro-angiogenic potential of the scaffolds was assessed using an ex ovo CAM assay previously reported by our group. Briefly, scaffolds were cut into 5 x 5 mm square pieces, sterilised with 70% IMS and washed three times with PBS. Filter paper discs soaked in either PBS (negative) or 10 ng/ml of vascular endothelial growth factor (VEGF) solution (positive) were used as controls. Fertile chicken eggs were incubated at 37.5°C and 35%–45% humidity in an egg incubator. At day 3 post-incubation, the embryos were transferred to a shell-less culture system with 75%–80% humidity and 37.5°C incubation temperature. At embryonic day (ED) 9, scaffolds were applied onto the developing CAMs and incubated. On ED12, scaffolds were excised following cryopreservation and 4% paraformaldehyde fixation. Angiogenesis was examined in all the scaffolds macroscopically by taking photos using a stereomicroscope. ImageJ software was used to analyse the macroscopic photos and calculate the vascular density and the number of bifurcation points for each scaffold. Scaffolds were sectioned to assess blood vessel infiltration using H&E staining.
Statistical analysis

GraphPad Prism 7 was used to analyse data. A minimum of \( n = 3 \) scaffolds were analysed per sample tested, unless otherwise stated and the data has been presented as mean ± standard error (SEM) of the mean. An Unpaired \( t \)-test with Welch’s correction was used to compare the differences in degradation of treated versus control scaffolds, and to compare NO production between activated and non-activated raw 264.7 cells. A non-parametric Dunn’s multiple comparison test was used to compare the differences in metabolic activity and percentage vascular area for each biomaterial tested. A one-way ANOVA was used to compare differences in the number of bifurcation points. A \( p \) value of <0.05 was considered significant.

Results

Material characterisation of composite scaffolds

Macroscopic appearance, SEM and EDX. Macroscopically, scaffolds appear as white-coloured sheet meshes (Figure 1(a)), indistinguishable from each other. However, when handling them, the FACaP scaffolds feel stiffer and tougher than FA ones. Scaffolds can be manufactured to varying sizes.

SEM showed that FACaP1 and FACaP2 scaffolds contained mineral deposits throughout their surfaces. The mineral deposits in FACaP1 exhibited a globular morphology, whereas in FACaP2, a plate-like morphology was seen (Figure 1(b)). SEM images also showed that FACaP scaffolds remained porous after mineral deposition. The control FA scaffolds did not show mineral deposition and the fibres of the material were distinctively visible (Figure 1(b)).

The EDX spectra revealed that the main elements in the mineral coatings of both FACaP1 and FACaP2 were Ca and P. In FACaP1 scaffolds, magnesium (Mg) was also present along with traces of sodium (Na) and chlorine (Cl) (Figure 2). The Ca/P ratio calculated for FACaP1 was \( 1.31 ± 0.06 \) and for FACaP2 was \( 1.18 ± 0.09 \) (mean ± SEM of multiple replicates). The control FA scaffolds did not show presence of Ca or P elements (Figure 2).

FTIR and XRD. FTIR spectra (Figure 3) showed the difference in FACaP versus control scaffolds. Phosphate group (PO\(_4\)) burst peaks were seen for FACaP1 samples at approximately 1050 cm\(^{-1}\) followed by a small shoulder peak at approximately 850 cm\(^{-1}\) which could be due to a hydrogen phosphate (HPO\(_4\)) group or a carbonate (CO\(_3\)) group or both. The small peak seen at approximately 1450 cm\(^{-1}\) for FACaP1 could be due to a CO\(_3\) group. A peak at approximately 600 cm\(^{-1}\), especially visible for FACaP2 samples, which could be due to a PO\(_4\) group. Moreover, spectra showed that PO\(_4\) peaks grow in intensity in FACaP2 samples compared to FACaP1 samples, suggesting deposition of a higher amount of a phosphate mineral phase in FACaP2. FTIR results suggested the presence of PO\(_4\) in FACaP scaffolds, and possibly both HPO\(_4\) and CO\(_3\) groups in FACaP1.

XRD diffractograms of FACaP1 did not show clear peaks for CaP phases as the CaP deposits in these scaffolds were very amorphous, and XRD is effective in displaying very crystalline phases (Figure 4). FACaP1 XRD diffractogram showed peaks for mainly calcite. For FACaP2 samples, XRD diffractograms revealed peaks that could correspond to hydroxyapatite (HA) and octacalcium phosphate (OCP). However, these peaks were broad indicating the CaP mineral phase/s present were not very crystalline. Considering that the Ca/P ratio calculated by EDX is approximately 1, FACaP2 could be
composed of a combination of CaP phases, for example OCP and amorphous calcium phosphate (ACP): Ca/P = 1.33 and Ca/P = 0.67–1.5 for OCP and ACP, respectively.\textsuperscript{15}

**Rheology.** For mechanical characterisation of the material, we calculated G’ for the different scaffolds. For control FA scaffolds, G’ was 11.24 ± 2.54 kPa, for FACaP1 was 75.22 ± 55.40 kPa, and for FACaP2 was 561.33 ± 109.79 kPa. Therefore, adding a CaP mineral coating to the fibrin-based matrix strengthened the material. A plate-like morphology (FACaP2) made the scaffold stronger than a globular morphology (FACaP1).

**Net weight and porosity.** There was a net increase in the weight of the FA scaffolds after immersion in SBF. This
accounted for a net increase of 76.60 ± 1.2% for FACaP1 and 79.59 ± 2.7% for FACaP2 (mean ± SEM of multiple replicates) (Figure 5(a)).

Mercury porosimetry data (Figure 5(b)) revealed that the porosity of control FA scaffolds is 93.77 ± 3.5%, whereas CaP coated scaffolds were 92.86 ± 0.2% porous in the case of FACaP1 and, 88.87 ± 1.9 % porous in the case of FACaP2 (mean ± SEM of three replicates). This suggests that coating FA scaffolds with CaP does not significantly alter the biomaterials’ overall porosity.

**Van Kossa staining.** CaP mineral deposits were seen throughout the cross-sections of the FACaP scaffolds as indicated in Figure 5(c). CaP mineral deposits were found evenly deposited in both FACaP scaffolds and absent from the control FA scaffolds.

**In vitro biodegradability.** The biodegradation assay (Figure 6) results demonstrated that even after 72 h remnants of DBM, FACaP1 and FACaP2 were still seen whereas the FA scaffolds were completely degraded. These results may indicate a slower degradation time for FACaP scaffolds compared to FA ones. In control conditions, scaffolds remained intact with minimal degradation after 72 h.

**In vitro cell work**

**In vitro response of inflammatory cells.** NO production was significantly higher in all the groups treated with LPS compared to without LPS. There was no further induction of NO production by RAW264.7 cells when in contact with the biomaterial compared to no biomaterial. There was no significant difference in NO production by RAW264.7 cells when cultured on either of the scaffolds (Figure 7).

**Cell viability and proliferation of osteoprogenitor cells.** Results showed that cells were viable under both +OM and −OM conditions with no dead cells seen in either of the scaffolds (Figure 8(a)). From day 1 to day 21 cells proliferated as

![Figure 3](image1.png)  
**Figure 3.** Representative FTIR spectra of scaffolds showing differences between control and FACaP scaffolds with PO₄ and CO₃ peaks seen in FACaP scaffolds only. A higher intensity peak for PO₄ was seen in FACaP 2 compared to FACaP 1.

![Figure 4](image2.png)  
**Figure 4.** Representative XRD diffractograms of scaffolds. FACaP1 showed peaks for mainly calcite, with its reference pattern shown in red. FACaP2 scaffolds showed peaks mainly for OCP (reference pattern in red) and HA (reference pattern in blue) with an inset showing a peak at ~4.6° confirming the presence of OCP.
indicated by the increase in metabolic activity (Figure 8(b)) and an increase in the number of cells seen in the 3D z-stack images. A significantly higher metabolic activity was seen in FACaP1 scaffolds compared to FACaP2 scaffolds at day 7. A significant increase was also seen from day 1 to day 14 and from day 7 to day 21 for FACaP1 scaffolds. Further, a significant increase in metabolic activity was also seen in FACaP2 scaffolds from day 1 to day 21, from day 7 to day 14 and from day 7 to day 21 (Figure 8(b)). Morphologically, the cells under +OM conditions were more confluent and appeared to be growing in clusters.

**Infiltration and migration of osteoprogenitor cells.** MC3T3-E1 cells infiltrated the scaffold as shown in Figure 9. The cells adhered and migrated throughout the depth of the scaffolds during the 28 days in culture. Cells appeared normal phenotypically with extended filopodia and cell-processes in both −OM and +OM conditions. Cells appeared aggregated and more confluent in +OM condition. H&E and DAPI staining of MC3T3-E1 cells in FACaP scaffolds under both −OM and +OM conditions showed that the cells were homogeneously distributed throughout the scaffold, similar to the control FA scaffolds.

**Osteogenic differentiation of osteoprogenitor cells.** Immunostaining of osteopontin, a protein present in the ECM of bone, showed that MC3T3-E1 cells in FACaP scaffolds under both −OM and +OM conditions; however, somewhat greater differentiation was observed in samples cultured under osteogenic conditions. Von Kossa staining revealed a marked increase in brown/black colour indicative of matrix mineralisation in FACaP scaffolds seeded with cells. FACaP2 scaffolds showed more mineralisation compared to FACaP1 scaffolds.
scaffolds as seen by more intense brown/black colour in the former scaffolds (Figure 10(b)).

**Ex ovo CAM assay**

We used an ex ovo CAM assay to assess the angiogenic capacity of the FACaP and FA scaffolds. Since fibrin is pro-angiogenic, we expected a greater vascular infiltration in FA scaffolds. Results confirmed the angiogenic potential of FACaP scaffolds where blood vessels were seen to infiltrate both FACaP scaffolds from the periphery all the way to the middle (Figure 11). The percentage vascular area for FA and FACaP1 scaffolds was significantly higher than the negative control PBS sample (Figure 11(b)). No significant differences were observed between the two FACaP scaffolds. In terms of the number of bifurcation...
Figure 7. NO production by RAW264.7 cells. Under +LPS condition all conditions showed a significant increase in NO production. This increase was, however, no more than NO production by RAW264.7 cells alone (No BM: no biomaterial). No significant differences were observed between FACaP and FA scaffolds. Data are presented as mean ± SEM of n = 3 for each condition. *p < 0.05. **p < 0.01. ***p < 0.001.

Figure 8. (a) Representative images of Live/Dead stained scaffolds at day 1 and day 28. Green fluorescence indicates live cells and were seen in all the scaffolds over 28 days under both +OM and −OM conditions. Note the confluent growth of cells under +OM conditions at day 28. (b) Cell proliferation in control and FACaP scaffolds (mean ± SEM of n = 4 for each condition). *p < 0.05. **p < 0.0001. Results show significant proliferation for cells cultured on the scaffolds over the culture period.

Discussion

In this study we developed novel fibrin-based composites intended as scaffolds in bone tissue engineering applications. A novel aspect of our proposed scaffolds is that they are made of fibrin and alginate. The base FA material was developed in our laboratory for the treatment of full-thickness skin injuries. This biomaterial has been extensively studied by our group and we have repeatedly shown its excellent cell adhesion and cell proliferative properties.11,12 Because of the advantages associated with the FA matrix, points, the three scaffolds obtained a significantly higher number than the negative control PBS. Additionally, FACaP1 had a significantly higher number of bifurcation points than FACaP2 and the positive control VEGF (Figure 11(b)). H&E staining of scaffolds (Figure 11(c)) excised from CAM membranes showed the presence of blood vessels throughout the depth of the scaffold confirming that blood vessels did not just superficially embed on the surface of the scaffolds but infiltrated them. All the scaffolds integrated well with the surrounding CAM and no foreign body giant cells were visible for any of the scaffolds.
we intended to explore if it would be suitable for bone regeneration. For this purpose, we used the SBF immersion method to biomimetically coat the FA scaffold with CaP. Since fibrin is a pro-angiogenic protein and alginate contains many carboxylic acid groups, which aid heterogeneous mineral nucleation, we hypothesised that together they could make a candidate biomaterial for bone applications. Coating biomaterials using SBF has been used for a variety of materials including metals, glasses and polymers; however, to the best of our knowledge, a fibrin-based biomaterial has never been used.

The two prototypes, FACaP1 and FACaP2 both contain a mineral coating representing a mixture of phases. CaP coatings have been widely studied for bone regeneration applications due to their potential for osteoconduction and in some cases osteoinduction. In FACaP1, the globular morphology of CaP is indicative of an amorphous calcium phosphate (ACP) phase containing Mg\(^{2+}\) ions, whereas for FACaP 2, the plate-like morphology of CaP may be indicative of OCP phase as well as HA. Taking into account the ratio of Ca/P for both prototypes, it can be conferred that both prototypes represent a mixture of CaP phases. In fact, both prototypes showed a lack of crystallinity and therefore, represent precursor CaP phases for subsequent bone mineralisation. Previous studies have shown that ACP can act as a transient phase which can easily be transformed to apatite via multiple intermediate stages. It has been shown before that the phase transformation in aqueous solutions occurs through dissolution of the parent phase followed by nucleation and growth of the new phase. In our study, FACaP1 was immersed in 5× concentrated SBF solution for 24 h, which led to the formation of a pre-nucleation complex. Further the EDX spectra revealed the presence of Mg, which inhibits crystal formation. It may be speculated that the pre-nucleation complex in FACaP1, when immersed in SBF-2 solution, which lacks Mg\(^{2+}\) ions and HCO\(_3^-\) ions, results in the formation of an OCP phase. Previous studies are consistent with our findings that HA formation in vitro and in vivo proceeds through a phase transformation from ACP to DCPD to OCP and finally to HA. For instance, Chahal et al. recently reported a composite of hydrogel poly(ethylene glycol) with ACP, where ACP transformed to HA via OCP after flushing with 100 mM Tris-HCl buffer.

**Figure 9.** (a) Representative H&E stained images of MC3T3-E1 seeded scaffolds at day 28 of culture. Pink colour is indicative of the eosin staining of the fibres and dark purple staining is indicative of cells (bar = 50 µm). (b) Representative SEM images of MC3T3-E1 seeded FACaP scaffolds under −OM and + OM conditions at day 28 of culture. Arrows point to cells integrated within the scaffolds. (c) Representative stitched images of DAPI stained scaffolds to show cell migration throughout the scaffold after 28 days in culture. Blue fluorescence shows cell nuclei of single cells (bar = 500 µm).
pH 7.4. In our study, the phase transformation occurred through immersions in two different 5× concentrated SBF solutions as previously described.32,38,39

The deposition of CaP in both FACaP1 and FACaP2 was observed throughout the depth of the scaffolds. This may be due to the high porosity of the FA matrix, which was not compromised even with CaP coating as shown by MIP results. The high interconnectivity of the pores has been shown to be an essential requirement for appropriate cell adhesion and proliferation.40 However, with increasing porosity, the mechanical strength of the biomaterial is often reduced. Both FACaP1 and FACaP2 scaffolds showed a higher viscoelastic modulus (G’) compared to the FA scaffold alone, while maintaining their high porosity. Further there was a net increase of over 70% in the dry weight of the scaffolds due to CaP coating. Together with Von Kossa staining, it can be conferred that an even coating of CaP was achieved on the scaffolds that allowed for increased stiffness without compromising the porosity of the scaffolds. For bone regeneration, a high overall porosity in conjunction with a gradient pore-size range is a prerequisite to allow for vascular infiltration and cell-adhesion and proliferation.40–42

It has been shown that proteases play an important role during bone healing and bone remodelling.43,44 When implanted in vivo, FACaP scaffolds would meet the

**Figure 10.** Representative images at day 28 of culture of (a) osteopontin immunostaining and (b) Von Kossa staining of cell seeded scaffolds under +OM and −OM conditions. Red fluorescence indicates osteopontin expression, blue fluorescence indicates DAPI stained cell nuclei. Osteopontin expression was clearly seen in FACaP scaffolds compared to control scaffolds and it was more abundant under +OM conditions. Black/brown colour in Von Kossa stained section indicates CaP mineral deposits. An intense staining of CaP mineral deposits was seen in FACaP scaffolds compared to FA control scaffolds.
Figure 11. (a) Representative macroscopic (left) and binary images (right) of the different scaffolds and controls. Blood vessels are seen in red colour (left panel) and black colour over white background of the scaffold (right panel). Please note that the image for C-was already published in Kohli et al.23 (b) Percentage vascular area and bifurcation points of blood vessels within the scaffolds. Data are presented as mean ± SEM of n = 6 for each condition (except for the number of bifurcation points for FA and FACaP 1 groups where n = 5). *p < 0.05. **p < 0.01. (c) Representative H&E stained images of FACaP and control scaffolds. Yellow arrows point at individual blood vessels. BM refers to the biomaterial and CAM refers to the surrounding CAM.
proteases present in the bone healing environment. Therefore, the serine protease trypsin was used in this study to mimic the in vivo environment. We used a high concentration of trypsin in order to accelerate the degradation process. The degradation rate of FACaP scaffolds was closer to DBM, indicating a slower degradation time due to the addition of CaP in the FA matrix. DBM is currently used clinically as a bone graft substitute; however, its use is limited by difficulty in manufacturing the scaffold, not being cost-effective and lacking angiogenic potential.

Since bone remodelling is a dynamic process involving many different cell types including inflammatory cells, we used RAW264.7 cells to assess NO production as a model of inflammation. While it is challenging to simulate the complexity of host immune response elicited by a biomaterial in an in vitro model, the assay used in this study gives an indication of the initial immune response by macrophages and allows the comparison of this response between biomaterials. We did not see an enhanced production of NO by RAW264.7 cells in either of our scaffolds. This may be due to the composition of the scaffold, that is, fibrin which has been shown to have a protective effect on macrophages, preventing a severe inflammatory response.

MC3T3-E1 cells on both prototypes, adhered, proliferated and migrated throughout the scaffold during the culture period of 28 days. Therefore, by coating the FA matrix with CaP, the scaffold still maintains its cell adhesion, migration and proliferation properties exhibited by FA in our previous work. Our results showed that cells directly attach to the CaP coating. The fact that cells were seen throughout the depth of the scaffolds shows that the porosity is optimal for cell infiltration. In a clinical scenario, this would mean that post-implantation, host cells would be easily able to penetrate and migrate through the scaffold and allow healing to take place. Further, the cells may be remodelling the CAcoated FA matrix with increased expression of osteopontin in FACaP scaffolds compared to the control scaffolds: even in the absence of osteogenic supplements, osteopontin expression was evident in FACaP scaffolds. It has previously been shown that CaP coatings, depending on their phase, may either suppress or enhance osteoblast cell proliferation and differentiation. Chou et al. showed that large plate-like structures of CaP coating significantly induced a higher expression of osteogenic markers compared to precursor phases. Another study showed that biomimetic carbonated apatite phase is most favourable for MC3T3-E1 cell proliferation and differentiation. These studies imply that the difference in osteoblast cell behaviour in vitro depends largely on the physicochemical properties of the CaP coatings as well as the surface topography and roughness of the substrate for cell-attachment. Both FACaP1 and FACaP2 allowed cell attachment, proliferation and differentiation. However, at an early time point, (day 7) FACaP1 showed a significantly higher cell proliferation compared to FACaP2. OCP, which promotes osteoblastic cell differentiation in vitro and bone regeneration in vivo, has been previously shown to induce a higher cell proliferation only after day 7, similar to our results, where FACaP2 showed a significant increase in the metabolic activity of MC3T3-E1 cells from day 7 in culture. The trend for MC3T3-E1 cell proliferation after day 7 was lower on FACaP2 scaffold compared to FACaP1 scaffolds. It may be speculated that the presence of OCP and/or HA phase in FACaP2, is inducing a switch from a proliferative state to a differentiated state. This is consistent with previous findings where a higher expression of osteogenic differentiation markers is seen on more matured CaP phases compared to precursor phases.

A recent study showed that fibrin along with biphasic calcium phosphate acts as an excellent composite material for bone regeneration compared to biphasic calcium phosphate alone, both in vitro and in vivo. Our proposed biomaterial with fibrin as the base material might show beneficial results for bone regeneration in vivo, too. Our ex ovo CAM assay showed that FACaP prototypes had enhanced capacity for angiogenesis. The FDA approved the use of CAM assays as a suitable model for testing biomaterials pre-clinically; however, only a handful of studies have used this method to examine initial tissue response to biomaterials. In our group, we use CAM assays to assess the angiogenic capacity and biocompatibility of our biomaterials. Both our prototypes are biocompatible as indicated by the absence of foreign body giant cells, as their presence is indicative of a foreign body reaction leading to implant failure. Further, both prototypes grafted well within the CAM mesenchyme, suggesting that the biomaterials were well-tolerated by the host tissue. In a CAM assay, blood vessels penetrate from the edges of the scaffold towards its centre, and it is representative of the vascularisation that would occur in vivo upon implantation of the scaffold. Quantification of the percentage of vascular area is a measurement of the extent of blood vessel infiltration. The blood vessel infiltration in our scaffolds was dependent not just on the composition of our biomaterial, but also on the porosity, as the filter disc soaked in VEGF did not show a higher vascular density compared to fibrin-based scaffolds. This is because of the high porosity of the scaffolds compared to the extremely low porosity of the filter disc. Adequate porosity and pore-size of the biomaterial are critical for bone formation both in vitro and in vivo, mainly to allow vascular infiltration and osteogenic differentiation. Both FACaP1 and FACaP2 provide sufficient porosity to allow cell and vascular infiltration. Additionally, bifurcation points are indicative of the vessel sprouting phase of the angiogenesis process, where pre-existing blood supply leads to vascular sprouting that then develops into mature blood vessels. Therefore, the scaffolds would encourage vessel sprouting culminating into the formation of mature blood
vessels. Particularly FACaP1 showed increased vessel sprouting potential, which could be due to the morphology of the CaP deposited on this material, which is easier to dissolve than the CaP morphology observed in FACaP2 as observed in our biodegradation assay. This faster dissolution process would make calcium ions more readily available, which are known to promote angiogenesis. It has been described in the literature that cellular phenotypic changes that take place during angiogenesis need calcium ion stimulation of gradient shifts.63 In summary, it has been shown that coupling of angiogenesis and osteogenesis is a key requirement for successful bone regeneration.64 Therefore, combining fibrin with CaP has enhanced potential for bone regeneration.3

Conclusion
We conclude that the proposed novel pro-angiogenic and osteogenic FACaP presented in this study appears very promising in their potential as scaffolds for bone tissue engineering as an alternative to bone grafts. FACaP can be easily manufactured using simple techniques and is very cost-effective. The work presented here gave useful insights into the potential of this biomaterial and merits further research in a pre-clinical model of bone defects prior to its clinical translation.

Acknowledgements
The authors would like to thank Dr Fred Jones from MCA services for help with MIP analyses. Authors would also like to acknowledge the use of Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza (Spain).

Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Dr Vaibhav Sharma and Dr Elena García-Gareta provided services to Smart Matrix Ltd (SML), established to take the humanised version of fibrin/alginate dermal replacement scaffold through the development stage and onto patients. Dr Sharma and Dr García-Gareta did not get directly paid for these services. The RAFT Institute, which invented and developed fibrin/alginate, had a service agreement with SML and the time that these two authors spent on services for SML were reimbursed to The RAFT Institute.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the Restoration of Appearance and Function Trust (UK, registered charity number 299811) charitable funds.

Research ethics
The ex ovo CAM assays conducted in this study was as per the guidelines of The Institutional Animal Care and Use Committee (IACUC), and the National Institutes of Health (NIH), USA.

ORCID iDs
Prasad Sawadkar https://orcid.org/0000-0003-2956-1592
Jonathan C Knowles https://orcid.org/0000-0003-3917-3446
Elena García-Gareta https://orcid.org/0000-0001-7062-9099

Data availability statement
Data generated and analysed during this study are included in this published article. Data and materials are available from the corresponding author subject to reasonable request and subject to the ethical approvals in place and material transfer agreements.

References
1. García-Gareta E, Coathup MJ and Blunn GW. Osteoinduction of bone grafting materials for bone repair and regeneration. Bone 2015; 81: 112–121.
2. Ahmed TAE, Dare EV and Hincke M. Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev 2008; 14(2): 199–215.
3. Noori A, Ashrafi SJ, Vazee-Ghaemi R, et al. A review of fibrin and fibrin composites for bone tissue engineering. Int J Nanomed 2017; 12: 4937–4961.
4. Mishra R, Roux BM, Posukonis M, et al. Effect of prevascularization on in vivo vascularization of poly(propylene fumarate)/fibrin scaffolds. Biomaterials 2016; 77: 255–266.
5. Ignjatovic N, Ajdukovic Z and Uskokovic D. New biocomposite [biphasic calcium phosphate/poly-DL-lactide-Coglycolide/biostimulative agent] filler for reconstruction of bone tissue changed by osteoporosis. J Mater Sci Mater Med 2005; 16(7): 621–626.
6. Wittmann K, Storck K, Muhr C, et al. Development of volume-stable adipose tissue constructs using polycaprolactone-based polyurethane scaffolds and fibrin hydrogels. J Tissue Eng Regen Med 2016; 10(10): E409–E418.
7. Schagemann JC, Chung HW, Mrosek EH, et al. Polyε-caprolactone/gel hybrid scaffolds for cartilage tissue engineering. J Biomed Mater Res Part A 2010; 93A(2): 454–463.
8. Panadero JA, Vikingsson L, Gomez Ribelles JL, et al. Fatigue prediction in fibrin poly-ε-caprolactone macroporous scaffolds. J Mech Behav Biomed Mater 2013; 28: 55–61.
9. Van Lieshout M, Peters G, Rutten M, et al. A knitted, fibrin-covered polycaprolactone scaffold for tissue engineering of the aortic valve. Tissue Eng 2006; 12(3): 481–487.
10. Perez RA, Kim M, Kim TH, et al. Utilizing core–shell fibrous collagen-alginate hydrogel cell delivery system for bone tissue engineering. Tissue Eng Part A 2014; 20(1–2): 103–114.
11. Sharma V, Patel N, Kohli N, et al. Viscoelastic, physical, and bio-degradable properties of dermal scaffolds and related cell behaviour. Biomed Mater 2016; 11(5): 055001.
12. García-Gareta E, Ravindran N, Sharma V, et al. A novel multiparameter in vitro model of three-dimensional cell ingress into scaffolds for dermal reconstruction to predict in vivo outcome. Biorev Open Access 2013; 2(6): 412–420.
13. Sharma V, Kohli N, Moulding D, et al. Design of a novel two-component hybrid dermal scaffold for the treatment of pressure sores. Macromol Biosci 2017; 17(11): 0185.
14. Levin A, Sharma V, Hook L, et al. The importance of factoroidal design in tissue engineering and biomaterials science: optimisation of cell seeding efficiency on dermal scaffolds as a case study. *J Tissue Eng* 2018; 9: 204173141878169.

15. Habraken W, Habibovic P, Epple M, et al. Calcium phosphates in biomedical applications: materials for the future? *Mater Today* 2016; 19(2): 69–87.

16. LeGeros RZ. Calcium phosphate-based osteoinductive materials. *Chem Rev* 2008; 108(11): 4742–4753.

17. Chahal AS, Schweikle M, Lian A, et al. Osteogenic potential of poly(ethylene glycol)-amorphous calcium phosphate composites on human mesenchymal stem cells. *J Tissue Eng* 2020; 11: 2041731420926840.

18. Kawai T, Kamakura S, Matsu K, et al. Clinical study of octacalcium phosphate and collagen composite in oral maxillofacial surgery. *J Tissue Eng* 2020; 11: 2041731419896449.

19. Kokubo T, Kushtiani H, Sakka S, et al. Solutions able to reproduce surface-structure changes in bioactive glass-ceramic A-W. *J Biomed Mater Res* 1990; 24: 721–734.

20. Oyane A, Kim HM, Furuya T, et al. Preparation and assessment of revised simulated body fluids. *J Biomed Mater Res* 2003; 65(A2): 188–195.

21. Dye JF, Sharma V, García-Gareta E, et al. Extracellular matrix-synthetic skin scaffold. United States patent US 10,357,592, 23 July 2019.

22. Kohli N, Ho S, Brown SJ, et al. Bone remodelling in vitro: where are we headed? *Bones* 2018; 110: 38–46.

23. Kohli N, Sawadkar P, Ho S, et al. Pre-screening the intrinsic angiogenic capacity of biomaterials in an optimised ex ovo chorioallantoic membrane model. *J Tissue Eng* 2020; 11: 204173142090162.

24. García-Gareta E, Hua J, Orera A, et al. Biomimetic surface functionalization of clinically relevant metals used as orthopaedic and dental implants. *Biomed Mater* 2017; 13(1): 015008.

25. Habibovic P, Barrere F, Barrère F, et al. Biomimetic hydroxyapatite coating on metal implants. *J Am Ceram Soc* 2002; 85(3): 517–522.

26. Li P, Ohtsuki C, Kokubo T, et al. Apatite formation induced by silica gel in a simulated body fluid. *J Am Ceram Soc* 1992; 75(8): 2094–2097.

27. Prabaharan M and Sivashankari PR. Prospects of bioactive chitosan-based scaffolds in tissue engineering and regenerative medicine. New Delhi, India: Springer, 2016, pp. 41–59.

28. Zhang R and Ma PX. Biomimetic polymer/apatite composite scaffolds for mineralized tissue engineering. *Macromol Biosci* 2004; 4(2): 100–111.

29. Murphy WL and Mooney DJ. Bioinspired growth of crystalline carbonate apatite on biodegradable polymer substrata. *J Am Chem Soc* 2002; 124(9): 1910–1917.

30. Murphy WL, Simmons CA, Kaigler D, et al. Bone regeneration via a mineral substrate and induced angiogenesis. *J Dent Res* 2004; 83(3): 204–210.

31. Jeong J, Kim JH, Shim JH, et al. Bioactive calcium phosphate materials and applications in bone regeneration. *Biomater Res* 2019; 23: 4.

32. Lin X, de Groot K, Wang D, et al. A review paper on biomimetic calcium phosphate coatings. *Open Biomed Eng J* 2015; 9: 56–64.

33. Denny I and Kuhn LT. Design and characterization of calcium phosphate ceramic scaffolds for bone tissue engineering. *Dent Mater* 2016; 32(1): 43–53.

34. Lotsari A, Rajasekharan AK, Halvarsson M, et al. Transformation of amorphous calcium phosphate to bone-like apatite. *Nat Commun* 2018; 9: 4170.

35. Putnis A. Mineral replacement reactions. *Rev Mineral Geochem* 2009; 70(1): 87–124.

36. Wang L and Nancollas GH. Dynamics of biomineralization and biodemineralization. *Mol Cells* 2010; 4: 413–456.

37. da Rocha DN, da Silva MHP, de Campos JB, et al. Kinetics of conversion of brushite coatings to hydroxyapatite in alkaline solution. *J Mater Res Technol* 2018; 7(4): 479–486.

38. Spanos N, Misirlis DY, Kanellopoulou DG, et al. Seeded growth of hydroxyapatite in simulated body fluid. *J Mater Sci Mater Med* 2006; 41(6): 1805–1812.

39. Chou YF, Chioo WA, Xu Y, et al. The effect of PH on the structural evolution of accelerated biomimetic apatite. *Biomaterials* 2004; 25(22): 5323–5331.

40. Karageorgiou V and Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. *Biomaterials* 2005; 26(27): 5474–5491.

41. Loh QL and Choong C. Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size. *Tissue Eng Part B Rev* 2013; 19(6): 485–502.

42. Polo-Correllas L, Latorre-Estevés M and Ramirez-Vick JE. Scaffold design for bone regeneration. *J Nanosci Nanotechnol* 2014; 14(1): 15–56.

43. Georges S, Ruiz Velasco C, Trivet C, et al. Proteases and bone remodelling. *Cytokine Growth Factor Rev* 2009; 20(1): 29–41.

44. Ortega N, Behonick D, Stickens D, et al. How proteases regulate verte morphogenesis. *Ann NY Acad Sci* 2003; 995: 109–116.

45. Shehadi JA and Elzein SM. Review of commercially available demineralized bone matrix products for spinal fusions: a selection paradigm. *Surg Neurol Int* 2017; 8: 203.

46. Hsieh JY, Smith TD, Meli VS, et al. Differential regulation of macrophage inflammatory activation by fibrin and fibrinogen. *Acta Biomater* 2017; 47: 14–24.

47. Wang J, de Boer J and de Groot K. Proliferation and differentiation of MC3T3-E1-E1 cells on calcium phosphate/chitosan coatings. *J Dent Res* 2008; 87(7): 650–654.

48. Orefio ROC, Griesss FCM, Planell JA, et al. Effects of novel calcium phosphate cements on human bone marrow fibroblastic cells. *Tissue Eng* 1998; 4(3): 293–303.

49. Chou Y, Huang W, Dunn J, et al. The effect of biomimetic apatite structure on osteoblast viability, proliferation, and gene expression. *Biomaterials* 2005; 26(3): 285–295.

50. Singh SS, Roy A, Lee BE, et al. MC3T3-E1-E1 proliferation and differentiation on biphasic mixtures of Mg substituted β-tricalcium phosphate and amorphous calcium phosphate. *Mater Sci Eng C* 2014; 45: 589–598.

51. Wang J, de Boer J and de Groot K. Proliferation and differentiation of osteoblast-like MC3T3-E1-E1 cells on biomimetically and electrolytically deposited calcium phosphate coatings. *J Biomed Mater Res Part A* 2009; 90(3): 664–670.

52. Samavedi S, Whittington AR and Goldstein AS. Calcium phosphate ceramics in bone tissue engineering: a review of properties and their influence on cell behavior. *Acta Biomater* 2013; 9(9): 8037–8045.

53. Kim BS and Lee J. Enhanced bone healing by improved fibrin-clot formation via fibrinogen adsorption on biphasic
calcium phosphate granules. Clin Oral Implants Res 2015; 26(10): 1203–1210.

54. Mangir N, Dikici S, Claeyssens F, et al. Using ex ovo chick chorioallantoic membrane (CAM) assay to evaluate the biocompatibility and angiogenic response to biomaterials. ACS Biomater Sci Eng 2019; 5(7): 3190–3200.

55. Moreno-Jimenez I, Kanczler JM, Hulsart-Billstrom GS, et al. The chorioallantoic membrane (CAM) assay for biomaterial testing in tissue engineering: a short term in vivo preclinical model. Tissue Eng Part C Methods 2017; 23(12): 938–952.

56. Moreno-Jiménez I, Hulsart-Billstrom G, Lanham SA, et al. The chorioallantoic membrane (CAM) assay for the study of human bone regeneration: a refinement animal model for tissue engineering. Sci Rep 2016; 6: 32168.

57. Naik M, Brahma P, Dixit M, et al. A cost-effective and efficient chick ex-ovo CAM assay protocol to assess angiogenesis. Methods Protoc 2018; 1(2): 19.

58. Zwadlo-Klarwasser G, Görtlitz K, Hafemann B, et al. The chorioallantoic membrane of the chick embryo as a simple model for the study of the angiogenic and inflammatory response to biomaterials. J Mater Sci Mater Med 2001; 12(3): 195–199.

59. Anderson JM. Inflammatory response to implants. ASAIO Trans 1988; 34(2): 101–107.

60. Anderson JM. Biological responses to materials. Annu Rev Mater Res 2001; 31(1): 81–110.

61. Bongio M, Lopa S, Gilardi M, et al. A 3D vascularized bone remodeling model combining osteoblasts and osteoclasts in a CaP nanoparticle-enriched matrix. Nanomedicine 2016; 11(Part I): 1073–1091.

62. Tadic D and Epple M. A thorough physicochemical characterisation of 14 calcium phosphate-based bone substitution materials in comparison to natural bone. Biomaterials 2004; 25: 987–994.

63. Patton AM, Kassis J, Doong H, et al. Calcium as a molecular target in angiogenesis. Curr Pharm Des 2003; 9(7): 543.

64. Grosso A, Burger MG, Lunger A, et al. It takes two to tango: coupling of angiogenesis and osteogenesis for bone regeneration. Front Bioeng Biotechnol 2017; 5: 68.